Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

tfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalininclude risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Tobago , July 25, 2014  The ... & Tobago Ministry of Health approved the introduction ... significantly increases the cure rate from Hepatitis C, ... the genotype 1 virus. Telaprevir is available in ... brand INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... 2014  AMETEK, Inc. (NYSE: AME ) ... as Vice President and General Manager, Engineered Medical ... Division. "I am pleased that Kurt has ... development experience, especially in the medical device industry, and ... continued growth and success of our medical components businesses," ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... 26, 2012 /PRNewswire-iReach/ -- ShelfX, provider ... the availability of the Vending Fridge. As the ... use a simple QR code scanner from their ... seamlessly purchase refrigerated products. The Vending Fridge can ...
... 26, 2012 Upsher-Smith Laboratories, Inc. ( http://www.upsher-smith.com ... pharmacokinetic (PK) profile of USL255, its once-daily, extended-release ... Annual American Academy of Neurology (AAN) Meeting.  One ... and equal doses of immediate-release (IR) topiramate at ...
Cached Medicine Technology:ShelfX Releases A Fridge That Knows What You Took 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 3Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 4Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 5
(Date:7/28/2014)... TherapySites, the leading website and ... its affiliation with the Illinois Association for Marriage ... TherapySites to continue to extend their online marketing solutions ... , “There has been a fundamental shift in the ... 3 billion Internet users, it is so important to ...
(Date:7/28/2014)... Wa (PRWEB) July 28, 2014 According to ... this is a comprehensive guide that will help people get ... to readers all the necessary information about heartburn and acid ... the truth about heartburn , and risk factors for reflux ... book will help people get rid of symptoms of reflux ...
(Date:7/28/2014)... Shore Points Capital announced today that ... Loftware, Inc., through a recapitalization of the Company led ... lead investor in Loftware for over nine years, a ... international provider of enterprise level software solutions for supply ... investment for us, and we are proud of everything ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... The first systematic analysis of hepatitis E virus (HEV) ... 3000 donors in England have HEV in their plasma. ... that around 1200 HEV-containing blood components (eg, red cells, ... transfused every year in England. , The study ... south east England between Oct, 2012 and Sept, 2013 ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... ... speaker, from standing on top of the world and sharing her story of hope and determination. ... Bayfield, WI (PRWEB) April 7, 2010 ... for this year,s attempt to climb the world,s highest peak. Last year,s successful climbers whose ...
... ... to Win an Appearance on National Television—or Win an Apple iPad™ in the “Best Seller ... ... lead to TODAY’S publishing of Gerry Czarnecki’s latest book… Lead with Love. This is ...
... An analysis by Mount Sinai researchers of over eight years ... that the relationship between high consumption of fruits and vegetables ... as commonly thought. The study is published online April 6, ... . It is widely believed that a diet rich ...
... Those with abnormalities at initial screening often didn,t have ... News) -- Black Americans are less likely than whites ... on a flexible sigmoidoscopy screening test, says a new ... be at greater risk for colorectal cancer and more ...
... , TUESDAY, April 6 (HealthDay News) -- The use of ... the past six years, even though these operations are ... more effective, a study finds. , "It was a bit ... said Dr. Richard A. Deyo, professor of family medicine and ...
... An approach designed to reduce HIV/STDs previously used ... community-based organizations (CBOs), an important component in national strategies ... "at risk" youths can be reached. , A ... tested whether a proven HIV/STD risk-reduction intervention would work ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail! 2Health News:‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail! 3Health News:Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer 2Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Complex Spinal Operations Soar Despite Drawbacks 2Health News:Complex Spinal Operations Soar Despite Drawbacks 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: